Qarc uc berkeley3/19/2023 But it must be combined with safe conditions and the right facilitators. But what is different here is the psychedelic catalyst that may fast-forward the process and can help achieve what might take someone several years to do in talk therapy, or that can help achieve what all other therapies have not. There is a lot of evidence about talk therapy that concludes that what matters is the therapist’s relationship with the client. Mainstream media articles often mistakenly focus on just the molecule itself: “Look what psilocybin does for you!” But it may likely be the substance that has the effect with a sophisticated course of support. What we see from the empirical work on psychedelics is that it’s not the substance alone that has the effect. Why did the center choose to train psychedelic facilitators, or guides, as part of its work? It is a very careful process we’re not just bringing in people and giving them drugs to see what happens. The psilocybin research at the UC Berkley Center for the Science of Psychedelics has to fully comply with federal regulatory processes for studies with scheduled substances. There’s also an emerging body of literature that speaks to some of these substances’ pro-social and other desirable effects. Their requests build on a sizable body of research evidence. Over the past several decades, however, enough researchers and practitioners have organized to re-approach the government to request federal approval for the scientific study of the efficacy of certain psychedelics in relieving depression, PTSD and other mental health disorders. While research on certain psychedelics once was legal, after the federal government classified most of them as “Schedule 1” drugs around 1970, they then became illegal, and funding for research into their therapeutic potential dried up. The study uses fMRI (functional magnetic resonance imaging) scans and psychophysics to investigate how a low dose of psilocybin affects perception and representation, among other things. Program and non-program participants can volunteer to participate, as healthy subjects, if they are deemed to be medically eligible, and they may be accepted into the study. Tina Trujillo: Research that includes human participants needs federal approval, and we have that, from the FDA. (Photo by Daphne Hougard) Berkeley News: With common psychedelics illegal federally, how is the UC Berkeley Center for the Science of Psychedelics able to do research - and with human subjects - into the efficacy of psychedelic medicines and psychedelic-assisted therapy? Tina Trujillo, a faculty member at the Graduate School of Education, helped launch and serves as faculty director of the Certificate Program in Psychedelic Facilitation at the UC Berkeley Center for the Science of Psychedelics. She said cohort members “want to be ready to do this work safely and ethically in legal spaces” in states where voters or legislatures are working to enact measures - like Oregon’s Measure 109, approved in 2020 - to allow the supervised administration of psilocybin, the “magic” in magic mushrooms, at licensed centers, or where opportunities exist in research studies and ketamine-assisted therapy clinics.īerkeley News recently talked with Trujillo about the new certificate program, how she became interested in psychedelic care, and about her own research into the emerging field of psychedelics education. Tina Trujillo, an associate professor in the Graduate School of Education (Berkeley Education), helped launch and serves as faculty director of the Certificate Program in Psychedelic Facilitation. The group of advanced professionals chosen for the nine-month, 175-hour program includes doctors, nurses, social workers, psychologists, chaplains and others. This fall, 24 people in a first-of-its-kind training program at the year-old UC Berkeley Center for the Science of Psychedelics are learning to safely guide patients’ psychedelic experiences in therapeutic and research settings. As a result, efforts to legalize their use also are on the rise. Today, psychedelics have been shown in recent, approved clinical trials to alleviate mental distress, even addiction. That law, signed by then-President Richard Nixon, halted what had been promising research into the drugs’ therapeutic and medicinal potential. There’s a resurgence in psychedelics, banned since 1970 by the federal Controlled Substances Act.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |